Index

Note: page numbers in *italics* refer to figures and tables.

A

abscess 118
  nonpuerperal mastitis 115, *117*
accessory glandular tissue 66
adenoma 82–83, *84–86*
  etiology *82*
  internal septations 83
  lactating 82
  mammography findings *82*
  mass lesions 253
  multiple foci 252
  nipple 82, 86
  solitary focus 251
  T1-weighted sequences 83, *84–86*
  T2-weighted sequences 83, *84–86*
  tubular 82, *85*
  ultrasonography findings *82*
adenomyoepithelioma 102
adenosis 91, 92, *93–95*
  blunt duct 92, *94*
  etiology *92*
  focal 251
  mammography *92*
  mass lesions 253
  microcystic 92
  microglandular 92
  multiple foci 252
  nodular 92, *95*
  nonmasslike lesions 255, *257, 258*
  sclerosing 92, *93, 94*
  ultrasonography *92*
age, breast parenchyma 64
AIM working group *266*
alveolar hyperplasia 91
alveoli 63
American College of Radiology (ARC)
  BI-RADS lexicon 45–46
  see also BI-RADS assessment
androgens, decrease causing gynecomastia 213
angiogenesis 33
  in fibrotic scar tissue 229
angiogenetic growth factors 33
angioma, cutaneous *123*
angiomatous hyperplasia, mass lesions 253
angiosarcoma 189
apocrine metaplasia 145
architectural distortion, diagnosis 259
areola 63
areolar region, focal enhancement 67
arteriovenous shunts, carcinoma-associated 33
artifacts 47–56
  breast implants 55
  cardiac flow 55
  ghosting 61
  out-of-phase imaging 53
  surface coils 56
  susceptibility 54
    cauterization during surgery 130
    hemangioma 100
    scar tissue 130, *131*
  see also error sources; motion artifacts
atypical ductal hyperplasia (ADH) 151, *152*
  flat epithelial atypia *152*
  peripheral papillomatosis with *143, 144*
  radial scar coincidence 145
  risk for breast cancer 151
axial slice orientation 19

B

basic fibroblast growth factor (bFGF) 33
BI-RADS assessment 45–46
  MRI-guided biopsy 264
  quality assurance 263, *264*
biopsy
  MR mammography after 6
  open 6
  stereotactic vacuum-assisted 223, 247
  US-guided core 247
  see also MRI-guided biopsy
blood/bloody fluid, hemorrhagic cysts 108
blooming 42
body building, gynecomastia *215*
BRCA mutations 243, *244*
  male carriers 216
  risk 249
BRCA1 mutation 243, *244*
  triple-negative breast cancer 190
breast
  atypical location of tissues 66
  blood supply 63
  involution 64
  morphology 63
  normal findings 63–74
  size asymmetry 65
  stroma 63
breast augmentation 201
  silicone injection 211, *212*
breast compression 8
  motion artifact reduction 50
breast-conserving therapy
  local recurrence 231
    extensive intraductal component in scar tissue 235
  plus radiotherapy 231
  plus radiotherapy/mastectomy 133, *134–135*
  R1 resection 136
  recurrence after 137, *138*
    local 231, 235
  second 231
breast implants *see* breast prostheses
breast parenchyma 63
  after mastectomy 133, *135*
  age 64
  alveoli 63
  asymmetry 65–66
    breast-conserving therapy 133, *134*
    enhancement 66
    focal 66
  cysts 103, *104*
  density patterns 69, *70*
  hemangioma 100, *101*
  hormone effects 71, 72
  hormone replacement therapy 72
  hyperemia 118
  interindividual variations 69, *70*
  intraindividual fluctuations 70–71
  lactation 73–74
  lobes 63
  lobules 63, 64
  menstrual cycle effects 70
  pregnancy 73
  residual after mastectomy 133, *135*
  signal intensity 17
  T1-weighted sequences 12
breast prostheses
  artifacts 55
  capsular contracture 206–207
  capsule 205
    fibrosis *207*
  capsulitis 206
  complications 265
    sagittal slice orientation with primary fat saturation sequences 19, *20*
  deformation 205, 207
  diagnostic MRI 203–211, *212*
    complications 206–211, *212*
    IR sequences 203–204
    normal findings 205–206
    orientation 203
    SE sequences 204
    swapped phase-encoding gradient *203*
  displacement 206
  double-lumen 205
  folds 206
  implant shell recession 207–208
  incomplete removal 211
  inverse type 205
  MRI follow-up after implantation 247
  periprosthetic capsule 207
  position 205
  prepectoral 205

Fischer, Practical MR Mammography. ISBN 9783131320322 © 2012 Georg Thieme Verlag/Thieme Publishers

radial folds 206, *210*
silicone gel bleeding 207, *208*
reverse double-lumen 205
rupture
complete 210, *211*
extracapsular 209–210
intracapsular 208–209, 210
shape 205, 207
shell 205
silicone gel bleeding 207, *208*
silicone leakage 209–210
single-lumen 205
subglandular 205
subpectoral 205
teardrop sign 207, *208*
breast reconstruction 201
autologous, diagnostic MRI after 201, *201–202*
flaps 201, *202*
MRI follow-up 247
breast surgery
abscess 118
cauterization 130
fat necrosis 125, *126–127*
focal mastitis *116*
R1 resection 136
residual carcinoma 136
scar tissue 130, *131–132*
seroma 128

C

calcifications
fat necrosis 125, *127*
hemangioma 100, *101*
medullary carcinoma 175
periprosthetic with capsular contracture 206, 207
plasma cell mastitis 119
see also microcalcifications
capsular contracture 206–207
granulomatous inflammation 207
capsulitis, breast prostheses 206
carcinoma of unknown primary (CUP) 232, *233–234*
carcinomas
adenosis differential diagnosis 92
architectural distortion 259
lymph node metastases *198*
with lymphangioma *43*
male 216
mass lesions 253, *254*
pseudoangiomatous stromal hyperplasia differential diagnosis 98
radial scar 145
residual after surgery 136
signal intensity 17
small 249, *250*
subcutaneous *43*
see also named types
cardiac flow artifacts 55
central tubular breast carcinoma, with radial scar *148*
certification of MRI 266
chemotherapy, neoadjuvant
localization clips/coils 225
MRI monitoring 245, *246*
chest wall, breast carcinoma
location 237, *238*
chocolate cyst 108
choline peak 31
collagen, scar tissue 130
compression device
coil-integrated mediolateral 8
motion artifact reduction 50
computer-aided diagnosis/detection (CAD) 28, *29*
MRM-CAD systems 267, *268*
contraindications to MR mammography 2
contrast-enhanced MRI 10
contrast medium (CM) 3, 5, 23
improper administration 49
materials 4
motion artifacts 49
paramagnetic 23–24, 33
reference points 49
T1-weighted precontrast examination 34, *35*
tolerance 23
underdosage 49
uptake
fluctuations in breast parenchyma 70–71
by hypervascularized tumors 17
by nipple 67
washout phenomenon 17
Cooper's suspensory ligaments 63
coronal slice orientation 19, *20*
cutaneous changes 123, *124*
cystosarcoma phyllodes, malignant 188
cysts 91
chocolate 108
complicated 109, *110–111, 254*
intracystic proliferation 109, *111*
wall thickening 109, *110*
hemorrhagic 108–109, *110–111*
inflamed 105, *106–107, 254*
intracystic proliferation 153, *154*
oil 125, *127*
simple 103, *104*

D

diagnosis/differential diagnosis 251–259
architectural distortion 259
foci
multiple 252
solitary 251
mass lesions 253, *254*
nonmasslike lesions 255, *256–258*
diagnostic criteria 34–46
diagnostic strategies 267
early breast cancer detection 267–268
diagnostic work-up 249, *249–250*
diffusion-weighted MRI 32
duct ectasia, chronic nonpuerperal mastitis 119, *120*
duct wall-enhancement, chronic nonpuerperal mastitis 119, *120*
ductal carcinoma in situ (DCIS) 155–163
adenosis differential diagnosis 92
classification 155–156, *157–162*
comedo type 155
cyst with intracystic proliferation *154*
enhancement 41
extensive intraductal component 156, *162*
with focal invasive tumor component 235, *237*
high-grade *154,* 155, *159–161*
intermediate type 155, *157–159*
intracystic *154*
intraductal papillary carcinoma 179
linear-branching enhancement 156, *160*
linear enhancement 156
low-grade *154,* 155, *156, 157*
masking by motion artifacts *51,* 52
mass lesions 156, *157, 161*
microcalcifications 247
minimal invasion *162*
MRI sensitivity 163
multifocality *239*
multiple foci 252
non-comedo type 155
nonmasslike lesions 255, *256, 257, 258*
Paget disease of the nipple association 186, *187*
papilloma progression risk 139
radial scar association *147, 148*
solitary focus 251
stromal fibrosis differential diagnosis 96
synchronous bilateral *241*
T1-weighted sequence
contrast enhanced 155, *156, 157, 158, 159, 160, 161, 162*
precontrast 155, *156, 157, 158, 160, 161*
T2-weighted sequence 155, *156, 157, 158*
transformation from atypical ductal hyperplasia 151
ductal dilatation, nonpuerperal mastitis 115, *117*
ductal hyperplasia 91
see also atypical ductal hyperplasia (ADH)
ductal intraepithelial neoplasia (DIN) 155
dynamic enhancement characteristics 41–44
initial signal increase 41–42

E

early breast cancer detection 249–250
diagnostics 267–268
echo time (TE) 4, 14, *15*
out-of-phase imaging 53
edema, peritumoral *43*
epitheliosis 91
error sources 47–48
contrast medium improper administration 49
inadequate windowing 60
incorrect pixel shifting 59
incorrect positioning 47, *48*
incorrect region of interest 58
inhomogeneous fat suppression 62

Fischer, Practical MR Mammography. ISBN 9783131320322 © 2012 Georg Thieme Verlag/Thieme Publishers

inhomogeneous silicone suppression 62
insufficient spatial resolution 58, *59*
substandard process 59
see also artifacts
estrogens, gynecomastia 213
evaluation protocols 44–46
examination of patient 2
protocol 30
timing 5
unestablished techniques 31–32
examination tables 268
extensive intraductal component (EIC)
ductal carcinoma in situ 156, *162*
invasive ductal carcinoma 165, *168*
preoperative local staging 235, *236–237*

F

fast low-angle shot (FLASH) sequences 1
fat necrosis 125, *126–127*
fat saturation
T2-weighed sequences 16
see also primary fat saturation sequences
fat suppression
inhomogeneous 62
lipomas 90
primary 12, *13*
fibroadenolipoma 112
fibroadenoma 75–76, *77,* 78–79, *80,* 81
etiology *75*
fibrotic 75, 76, *78, 79, 80*
T1-weighted sequences 78–79, *80*
giant 79, 81
halo sign 76, *77*
intracanalicular 75
with invasive ductal carcinoma *168*
juvenile 79, 81
malignant phyllodes tumor differential diagnosis 188
mammography findings *75*
mass lesions 253, *254*
multiple foci 252
pericanalicular 75
phyllodes 87, *88–89*
solitary focus 251
T1-weighted sequences 76, *77, 78, 79*
T2-weighted sequences 76, *77, 78*
ultrasonography findings *75*
see also myxoid fibroadenomas
fibroblast growth factor, basic (bFGF) 33
fibrocystic breast condition/change 91
fibrosis
breast prosthesis capsule *207*
mass lesions 253
nephrogenic systemic 24
stromal 91, 96, *97*
fibrous histiocytoma, malignant 189
field of view (FOV) 10, 18
coronal slice orientation 19, *20*
field strength 9
fine-needle aspiration
hematoma *129*
seroma *128*
fine-needle biopsy, MR mammography after 6
flat epithelial atypia (FEA) *152*
flip angle 10
foci 37
adenomyoepithelioma 102
multiple 252
solitary 251
Fourier transform 11
frequency-encoding gradient 55

G

gadolinium-DTPA 23, 33
during lactation/pregnancy 24
renal insufficiency 24
underdosage 49
galactocele 74
galactography 6
galactophoritis 74, 119
gelatinous carcinoma *see* mucinous carcinoma
ghosting 61
Göttingen Optipack 249, *250,* 265
Göttingen score 44, *45, 46*
mass lesions 253
MRI BI-RADS comparison 46
nonmasslike lesions 255
gradient-echo (GE) sequences 3, 4, 14
granuloma, mass lesions 253
granulomatous mastitis
lobular 119
scar tissue *131*
growth factors, angiogenetic 33
gynecomastia 213, *214–215*
male breast cancer differential diagnosis 216
pathological 213, *214–215*
physiological 213
T1-weighted sequence 213, *214–215*

H

halo sign 76, *77*
adenomas 83
hamartoma *112*
malignant phyllodes tumor 188
simple cysts 103, *104*
hamartoma 112, *113–114*
glandular component 112, *113*
lipomatous component 112, *114*
malignant phyllodes tumor differential diagnosis 188
mass lesions 253
organoid internal structures 112, *113, 114*
pseudocapsular demarcation 112, *113*
hemangioma 100, *101*
hematogenous metastases 232
hematoma 129
hemorrhage, intramammary 129
hemosiderin precipitation, hematoma *129*
hereditary breast cancers 243, *244*
histiocytoma, fibrous malignant 189
hormonal stimulation
gynecomastia 213
limitations of MRI 266
nonmasslike lesions 255, *258*
hormone levels
breast parenchyma uptake of contrast medium 71, 72
examination timing 5
fibrocystic breast conditions 91
lactation/pregnancy 192
hormone replacement therapy (HRT) 5
breast parenchyma 72

I

image
quality 266
reconstruction 11
volume 18
image-based reconstruction after Fourier transform 11
image postprocessing 25, *26,* 27
automated 28, *29*
pixel shifting 59
image subtraction 25
T1-weighted sequences 12
implant shell recession 207–208
in-phase imaging 14, *15*
indications for breast MRI 229–250
carcinoma of unknown primary 232, *233–234*
early detection 249–250
follow-up after breast reconstruction with prosthesis implant 247
increased breast cancer risk 243, *244*
monitoring during neoadjuvant chemotherapy 245, *246*
preoperative local staging 235, *236,* 237–238, *239,* 240, *241,* 242
problem cases 247, *248*
indurative mastopathy 145
infiltrating duct carcinoma, poorly infiltrating 184
inflammation
capsulitis with breast prostheses 206
cysts 105, *106–107*
fat necrosis 125, *127*
granulomatous 130, *131–132,* 207
scar tissue 130, *131, 132*
inflammatory breast cancer 184, *185*
information for patient 2
initial signal increase 41–42
intercostal artery 63
internal septations 39
adenomas 83
complicated cysts *109*
dark *39, 77,* 78, 79
enhancing *39*
hypervascularized 38–39
myxoid fibroadenomas 16, 36, 38–39
simple cysts 103
intracystic papillary carcinoma 179
intracystic papilloma *111*
intracystic septations, simple cysts 103
intraductal carcinoma *see* ductal carcinoma in situ (DCIS)
intraductal papillary carcinoma 179

intraductal tumors, adenosis differential diagnosis 92
invasive ductal carcinoma (IDC) 165, *166–169*
contralateral to tubular carcinoma *183*
definition 165
extensive intraductal component 165, *168*
with fibroadenoma *168*
with high water content 165, *169*
lymph node metastases *234*
locoregional *233*
male *216*
mammographically occult *250*
MRI influence on therapeutic strategy 242
MRI monitoring during neoadjuvant chemotherapy *246*
MRI resolution of problem case *248*
MRI sensitivity 194
multicentricity *241*
multiple foci *239,* 252
pectoral muscle infiltration *237*
peritumoral edema 165, *166, 167*
recurrence *230*
with rim-enhancement 165, *169*
solitary focus *251*
synchronous bilateral *241*
T1-weighted sequence
contrast enhanced 165, *166–169*
precontrast 165, *166–167*
T2-weighted sequence 165, *166–167, 169*
time-signal intensity analysis 165, *167–168*
triple-negative breast cancer *190, 191*
invasive lobular carcinoma (ILC) 170, *171–174*
definition 170
diffuse 170, *171–173*
MRI influence on therapeutic strategy 240, 242
MRI sensitivity 194
multifocality *239*
nodular 170, *173–174*
nonmasslike lesions 255, *257, 258*
papillomatosis with *144*
pectoral muscle infiltration *237*
peritumoral edema 170, *173*
recurrence *230*
synchronous bilateral 240
T1-weighted sequence
contrast enhanced 170, *171–172, 174*
precontrast 170, *171–172, 173–174*
T2-weighted sequence 170, *173, 174*
ultrasound 194
invasive papillary carcinoma 179, *180–181*
differential diagnosis 179
papilloma progression risk 139
T1-weighted sequence 179, *180–181*
T2-weighted sequence 179, *180–181*
invasive tubular carcinoma, MRI-guided vacuum-assisted biopsy *222*
inversion recovery (IR) sequence
breast prosthesis diagnostic MRI 203–204
silicone-sensitive/-suppressed 210
iris diaphragm phenomenon 42

K

k-space-based reconstruction before Fourier transform 11

L

lactation
breast carcinoma 192, *192–193*
breast parenchyma 73–74
gadolinium-DTPA 24
hormone levels 192
mammary duct dilatation 74
puerperal mastitis 115
lactiferous sinuses, subareolar 63
large-core biopsy, MR mammography after 6
Larmor frequency 3
latissimus dorsi myocutaneous flap technique 201
lesions
detection time frame 17
malignant and associated findings 43, *43–44*
see also foci; masses/mass lesions; nonmasslike lesions
linguine sign 209, *210*
lipofibroadenoma 112
lipomas 90
lipomastia 213, *215*
lipomatous tissue
scar tissue 130
tumor recurrence 137, *138*
liponecrosis microcystica calcificata 125
lobular carcinoma in situ (LCIS) 149, *150*
classification 149
radial scar coincidence 145
lobular carcinoma, invasive 96
lobular hyperplasia 91
lobular intra-epithelial neoplasia (LIN) *222*
lobuli
multiple foci 252
solitary focus 251
local recurrence
detection 231
extensive intraductal component in scar tissue 235
scar tissue
differentiation 229, *230,* 231
extensive intraductal component 235
localization clips/coils 225, *226*
localization wires 225
lumpectomy, MR mammography after 6
lymph nodes
axillary *197, 198*
metastases 232, *234,* 240
diagnostics 195, *196–200*
fatty hilus 195, *196, 198*
inflammatory changes 195, *196, 198*
intramammary *197, 199*
mass lesions 253
solitary focus 251
locations 195, *196–197, 199*
mass lesions 195, *196,* 253
metastases 195, *198, 199, 200*
carcinoma of unknown primary 232, *233, 234*
with inflammatory breast cancer *185*
staging 240
morphology 195, *198, 200*
normal *196, 199*
parasternal 195, *199, 200*
reactive hyperplasia *199*
rim-enhancement *196*
size 195, *198, 200*
T1-weighted sequence
contrast enhanced 195, *196–197*
precontrast 195, *196*
T2-weighted sequence 195, *196, 198*
lymphadenopathy *44*
lymphangioma *43*
lymphogenous spread 195
breast carcinoma during pregnancy *192*

M

macrocalcifications *see* calcifications
magnetic resonance elastography (MRE) 31
magnetic resonance imaging (MRI)
BI-RADS 3 lesions 263
BI-RADS 4/5 lesions *264*
certification 266
cost reduction 267
density patterns 69, *70*
detection rate 250
diagnostic
after autologous breast reconstruction 201, *202*
breast prostheses 203–211, *212*
examination modification 267
examination tables 268
findings detection/characterization *268*
historical aspects 1
indications 265
invasive ductal/lobular carcinoma sensitivity 194
limitations 266
malignant changes 194
men 213, *214–215,* 216
methods *261,* 267, *268*
minimum requirements for examination 261
principles 3–4
quality check 262
screening approach *268*
specificity 265
technique *261,* 265
value 265
magnetic resonance spectroscopy (MRS) 31
magnetization transfer (MT) 12
male breast cancer 216

Fischer, Practical MR Mammography. ISBN 9783131320322 © 2012 Georg Thieme Verlag/Thieme Publishers

malignancy
BI-RADS risk assessment 45, *46*
characteristics of male breast cancer 216
radial scar coincidence 145
scar tissue differential diagnosis 130
vascularized 229
malignant change 165–194
breast carcinoma during pregnancy/lactation 192, *192–193*
inflammatory breast cancer 184, *185*
invasive ductal carcinoma 165, *166–169*
invasive lobular carcinoma *144,* 170, *171–174*
invasive papillary carcinoma 179, *180–181*
papilloma progression risk 139
medullary carcinoma 175, *176*
MRI 194
mucinous carcinoma 177, *178*
phyllodes tumor 188
sarcoma 189
triple-negative breast cancer 190, *190–191*
tubular carcinoma 182, *183*
ultrasound 194
malignant fibrous histiocytoma 189
malignant lesions, associated findings 43, *43–44*
malignant phyllodes tumor 188
mammary ducts 64
dilatation in lactation 74
mammary dysplasia 91
mammary papilla *see* nipple
mammographically occult tumors 250
masses/mass lesions 37–39
adenomyoepithelioma 102
diagnosis 253, *254*
differential diagnosis *253–254*
endotumoral changes *254*
enhancement pattern 38–39
Göttingen score *45, 46,* 253
granuloma 253
margins 38
motion artifacts *50*
pseudoangiomatous stromal hyperplasia 98, *99*
shape 38
stromal fibrosis differential diagnosis 96, *97*
masslike enhancement, breast parenchyma uptake of contrast medium 71
mastectomy
breast parenchyma 133, *135*
recurrence after 137, *138*
residual parenchyma 133, *135*
mastitis
acute 115
granulomatous
lobular 119
scar tissue *131*
inflamed cysts *107*
lobular 119
nonmasslike lesions 255, *256, 257, 258*
nonpuerperal 115, *116–117*
chronic 119, *120*
diffuse *117*
inflammatory carcinoma differential diagnosis 184
nonmasslike lesions *258*
plasma cell 119
puerperal 115
abscess 118
matrix 18
maximum intensity projection (MIP) technique 19, *20,* 27
motion artifact *51*
medullary carcinoma 175, *176*
atypical 175
T1-weighted sequence
contrast enhanced 175, *176*
precontrast 175, *176*
T2-weighted sequence 175, *176*
men
breast MRI 213, *214–215,* 216
male breast cancer 216
menstrual cycle
breast parenchyma uptake of contrast medium 70
examination timing 5
fibrocystic breast conditions 91
metal clips, susceptibility artifacts 54
metastases
breast skin 137
carcinoma of unknown primary syndrome 232, *233–234*
hematogenous 232
intramammary 252
locoregional 232
lymph nodes 195, *198, 199, 200*
carcinoma of unknown primary 232, *233, 234*
with inflammatory breast cancer *185*
staging 240
microcalcifications
ambiguous 249
atypical ductal hyperplasia *151*
ductal carcinoma in situ 247
lobular carcinoma in situ 149
radial scar *145*
suspicious 249
tubular carcinoma 182
microcysts *104*
mixed tubular carcinoma 182
Mondor disease 121, *122*
Montgomery gland, inflamed 67
Morgagni's tubercles 63
motion artifacts 8, 49, 50–52
classification 51–52
corrective measures 52
documentation 51–52
false-positive/-negative 51, *52*
ghosting *61*
limitations of MRI 266
pectoral muscle infiltration 237, *238*
postprocessing 59
subtraction images 51
MRI-guided biopsy 1, 217
biopsy and localization grid 217, *218*
classification of pathological findings *221*
computer-aided calculation of puncture coordinates 217
equipment 217, *218*
large-core 219, *220*
open 264
percutaneous *221*
post-and-pillar targeting equipment 217, *218*
vacuum-assisted
checklist *223*
diagnostic 219, *220–221,* 222–223
equipment 219, *220*
follow-up examination 222
good practice recommendations 219
hematoma *129*
histological verification of findings 242
indications 219
mass lesion *222*
objectives 219
postbiopsy check 222
quality assurance 263, *264*
scar tissue 130, *131, 132*
study results 223
therapeutic 224
MRI-guided interventions 217–228
equipment 217
localization 225, *226–228*
checklist *228*
direct 225
equipment 225, *225–226*
procedure *227, 228*
target volume 225
procedures 217
surface coils 217, *218*
MRM-CAD systems 267, *268*
mucinous carcinoma 177, *178*
multicentricity 238, 240, *241*
multifactorial evaluation protocols 44
multiplanar reconstruction (MPR) 27
myxoid fibroadenomas 75
benign phyllodes tumor differential diagnosis 87
internal septations 16, 36, 38–39, *77,* 78, 79
T1-weighted sequences 76, *77,* 78
T2-weighed sequences 16
T2-weighted sequences 76, *77*

N

N-staging 240
needles, broken parts 54
neonatal gynecomastia 213
nephrogenic systemic fibrosis 24
nevus, skin *124*
nipple
adenoma 82, 86
creviced unilateral/bilateral 68
form variants 68
incorrect positioning *48*
inverted 68
Paget disease 186, *187*
papillary adenoma 139
physiological enhancement 67
retraction *43*
thickening *43*
unilateral enhancement 68

Fischer, Practical MR Mammography. ISBN 9783131320322 © 2012 Georg Thieme Verlag/Thieme Publishers

nonmasslike enhancement 40–41
asymmetry 41
distribution 40
internal enhancement characteristics/pattern 41
motion artifacts 51
nonpuerperal mastitis 115, *116*
pseudoangiomatous stromal hyperplasia 98, *99*
symmetry 41
tumor recurrence *138*
nonmasslike lesions
diagnosis 255, *256–258*
differential diagnosis *256–257*
diffuse unilateral/bilateral enhancement *258*
ductal enhancement 255
Göttingen score 255
interstitial enhancement 255
linear-branching enhancement *256*
linear enhancement *256*
regional enhancement *257*
segmental enhancement *257*
nutritional supply to tumors 33

O

occult inflammatory breast cancer (OIBC) 184, *185*
oil cysts 125, *127*
open breast coils *4,* 5, 217, *265*
out-of-phase imaging 14, *15,* 53
ovarian carcinoma risk 243, *244*

P

Paget cells 186
Paget disease of nipple 186, *187*
pain, breast 5
papillary adenoma of the nipple 139
papilloma 139, *140–144*
benign 139
classification 139
etiology *140*
galactography *140*
intraductal
large solitary 139, *141*
peripheral 139, *142–144*
small solitary 139, *140, 141*
mammography *140*
mass lesions 253
MRI-guided vacuum-assisted therapeutic biopsy 224
multiple foci 252
solitary focus 251
solitary intraductal 139
solitary retromamillary *141*
transformation risk 139, *140*
ultrasonography *140*
papillomatosis 91, 139
classification 139
hypervascularization *144*
with invasive lobular carcinoma *144*
juvenile 139
linear *142*
nonmasslike lesions 255, *256, 257*
peripheral
with ADH *143, 144*
regional *143*
segmental *142*
parallel imaging 11
paramagnetic substances 23–24, 33
patient(s)
movements during examination 50
preparation 2
patient positioning 7
examination tables 268
incorrect 47, *48*
lateral displacement *47*
supine *48*
pectoral fascia 63
pectoral muscle 63
relaxation causing motion artifact *50*
tumor infiltration *44*
pectoral muscle infiltration
motion artifacts 237, *238*
preoperative local staging 235, 237, *238*
perimamillary enhancement, atypical 67
phase-encoding gradient 21, *22,* 55
phyllodes tumor
benign 87, *88–89,* 188
bifocal *89*
malignant 188
mass lesions 253
solitary focus 251
pixels, incorrect shifting/negative 59
port systems, susceptibility artifacts 54
portacaths, susceptibility artifacts 54
postinitial signal course 42
precessional frequency 3
pregnancy
breast carcinoma 192
breast parenchyma 73
gadolinium-DTPA 24
hormone levels 192
preoperative local staging 235, *236,* 237–238, *239,* 240, *241,* 242
extensive intraductal component 235, *236–237*
false-positive findings 242
MRI influence on therapeutic strategy 240, 242
multicentricity 238, *240, 241*
multifocality 238, *239*
N-staging 240
pectoral muscle infiltration 235, 237, *238*
reliability 242
strategies 242
synchronous bilateral breast cancer 240, *241*
therapy-relevant information 240, 242
tumor size 235
primary fat saturation sequences
sagittal slice orientation 19, *20*
T1-weighted sequences 12, *13*
prosthesis expanders, metal plates causing susceptibility artifacts 54
pseudoangiomatous stromal hyperplasia (PASH) 98, *99*
pseudogynecomastia 213, *215*
pseudopapillary lesions, papilloma differential diagnosis 139
pubertal gynecomastia 213
pulse sequences 3

Q

quality assurance 261–264
minimum requirements for MRI examination 261
MRI-guided vacuum-assisted biopsy 263, *264*
quality check 262
special cases 263–264
written reports 262, *263*

R

R1 resection 136
radial scar 92, 145, *146–148*
architectural distortion 259
classification 145
DCIS association *147, 148*
MRI-guided vacuum-assisted biopsy *222*
tubular carcinoma 182
central *148*
radial sclerosing lesion 145
radiofrequency (RF) excitation 3
radiofrequency (RF) pulse 4
radiotherapy
adjuvant with breast cancer surgery 231
breast-conserving therapy 133, *134–135,* 231
MR mammography after 6
nonmasslike lesions *258*
skin thickening 133, *134*
vascularization of breast *134*
recanalization, Mondor disease 121, *122*
receiver coils, quality assurance test *56*
recurrence
after breast-conserving therapy 137, *138*
after mastectomy 137, *138*
detection 231
lipomatous tissue 137, *138*
scar tissue differential diagnosis 130
see also local recurrence
reduction mammoplasty 201
region of interest (ROI) 25, *26*
automatically defined 28
contrast-enhancing 41
incorrect 57
relaxation time 3
renal insufficiency, gadolinium-DTPA 24
repetition time (TR) 10
resection, R1 136
retraction phenomenon *248*
rim enhancement 38, 39
complicated cysts *109*
fat necrosis *126, 127*
inflamed cysts 105, *106*
intraductal papilloma 139
risk, increased 243, *244*
RODEO (rotating delivery of excitation off-resonance) sequence 12

Fischer, Practical MR Mammography. ISBN 9783131320322 © 2012 Georg Thieme Verlag/Thieme Publishers

S

sagittal slice orientation 19, *20*
salad-oil sign 209
saline, inadequate flushing 49
sandwich protocol 21, *22*
sarcoma 189
scar tissue 130, *131–132*
  hyperemia 137
  local recurrence
    differentiation 229, *230,* 231
    extensive intraductal component 235
  postoperative 259
  tumor angiogenesis 229
  vascularization *132*
sclerosing adenosis 145
sclerosing papillary proliferation 145
screening approach *268*
sedimentation, hemorrhagic cysts 108
segmentectomy, recurrence after *138*
senescent gynecomastia 213
seroma 128
serratus muscle, anterior 63
shear stiffness of lesions 31
shrinking sign *248*
signal intensity
  breast parenchyma 17
  carcinomas 17
  homogeneity assessment 56
  initial increase 41–42
  kinetic pattern 42
  postinitial course 42
  sufficiency assessment 56
silicone
  bleeding of gel 207, *208*
  free 211, *212*
  inhomogeneous suppression 62
  injection into breast material 211, *212*
  leakage 209–210
  resonant frequency 203–204
siliconoma 211
skin, breast 63
  changes 123, *124*
  inflammatory carcinoma 184
  metastases 137
  Paget disease of the nipple 186
  retraction *43*
  thickening after radiotherapy 133, *134*
slice images, subtraction 36
slice orientation 19, *20*
slice thickness 18
snow-peak effect *51*
sources of error *see* error sources
spatial encoding 3
spatial resolution 1, 18
  insufficient 58, *59*
  surface coils 4
spin-echo (SE) sequences 3, 4
  breast prostheses diagnostic MRI 204
  T2-weighed 16
sponge attachment, ultrasound-visible for localization clips/coils 225, *226*
sternal wire cerclages, susceptibility artifacts 54
stromal fibrosis 91, 96, *97*
stromal hyperplasia, pseudoangiomatous 98, *99*
subareolar lactiferous sinuses 63
subcutaneous lipoma 90
subscapular artery 63
subtraction images 25, *26,* 27
  inadequate technique *58*
  motion artifacts 51, 52
  substandard process 59
subtraction slice images 36
surface coils 4–5
  artifacts 56
  magnetic resonance elastography 31
  MRI-compatible 217, *218*
  open breast *4,* 5, 217, *265*
swapping of phase-encoding gradient 21, *22*

T

T1 relaxation time 3, 4
T1-weighted sequences 12, *13*
  contrast-enhanced examination 36–46
  dynamic enhancement characteristics 41–44
  juvenile fibroadenoma 81
  lesion types 37–41
  precontrast examination 34, *35*
T2 relaxation time 3, 4
T2-weighted sequences 16
  assessment 36
  before dynamic examination 47
  water-sensitive 16
teardrop sign 207, *208*
temporal resolution 17
therapeutic strategy 267
  MRI influence in preoperative local staging 240, 242
thoracic arteries, internal/lateral 63
thoracoacromial artery 63
thoracodorsal artery 63
thoracoepigastric flap technique 201
three-dimensional (3D) techniques 3, 10
thrombophlebitis 121
time-signal intensity curve (TIC) 21
  analysis of enhancing lesions 25, *26*
  computer-aided diagnosis 28
  contrast-enhancing ROI 41
track phenomenon 119, *120*
TRAM (transverse rectus abdominis myocutaneous) flap technique 201, *202*
transmitters, quality assurance test *56*
triple-negative breast cancer 190, *190–191*
  hereditary *244*
  pectoral muscle infiltration *238*
  rim-enhancement 190, *191*
tubular carcinoma 182, *183,* 259
  central with radial scar *148*
  invasive *222*
tubulosaccular secretory units 63
tumor angiogenesis 33
tumors
  contrast enhancement 33
  intraductal 92
  mammographically occult 250
  MRI-guided localization 225, *226–228*
  nutritional supply 33
  perfusion increase 33
  size and slice thickness 18
  see also named types
turbo spin-echo (TSE) sequences, T2-weighted 16
two-dimensional (2D) techniques 3, 10

U

ultrasound (US)
  adenomas *82*
  adenosis *92*
  benign phyllodes tumor *87*
  detection rate 250
  fibroadenoma *75*
  invasive ductal carcinoma sensitivity 194
  invasive lobular carcinoma sensitivity 194
  malignant change 194
  papilloma *140*
  problem cases 247
  second-look 249, *250*
ultrasound-visible sponge attachment for localization clips/coils 225, *226*

V

vascular endothelial growth factor (VEGF) 33
vein ectasia, Mondor disease 121
viscoelastic property of tissue 31

W

wall enhancement 38
  ductal in chronic nonpuerperal mastitis 119, *120*
washout phenomenon 17, *23*
  angiogenetic processes 33
water-sensitive T2w images 16
windowing, inadequate 60
wound healing, scar tissue 130, *131*
written reports 262, *263*

X

x-ray mammography
  detection rate 250
  malignant change sensitivity compared with MRI/US 194
  problem cases 247, *248*

Z

zebra protocol 21, *22*

Fischer, Practical MR Mammography. ISBN 9783131320322 © 2012 Georg Thieme Verlag/Thieme Publishers